A review by Tong et al. examining the mechanisms of action and clinical applications of Trop-2-targeted ADCs in TNBC revealed that these agents facilitate immune reprogramming, modulate the tumor microenvironment, and enhance anti-tumor efficacy [32]. Here, TACSTD2 is linked to neoplasm.